Literature DB >> 19584072

Emerging molecular technologies for identifying the risk of second cancers.

Susan T Mayne1, Stephen B Gruber.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19584072      PMCID： PMC2733247          DOI： 10.1158/1940-6207.CAPR-09-0101

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN： 1940-6215


× No keyword cloud information.
  14 in total

Review 1.  Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations.

Authors:  Lois B Travis; Charles S Rabkin; Linda Morris Brown; James M Allan; Blanche P Alter; Christine B Ambrosone; Colin B Begg; Neil Caporaso; Stephen Chanock; Angela DeMichele; William Douglas Figg; Mary K Gospodarowicz; Eric J Hall; Michie Hisada; Peter Inskip; Ruth Kleinerman; John B Little; David Malkin; Andrea K Ng; Kenneth Offit; Ching-Hon Pui; Leslie L Robison; Nathaniel Rothman; Peter G Shields; Louise Strong; Toshiyasu Taniguchi; Margaret A Tucker; Mark H Greene
Journal:  J Natl Cancer Inst       Date:  2006-01-04       Impact factor: 13.506

2.  A powerful method of combining measures of association and Hardy-Weinberg disequilibrium for fine-mapping in case-control studies.

Authors:  Kijoung Song; Robert C Elston
Journal:  Stat Med       Date:  2006-01-15       Impact factor: 2.373

3.  A risk model for prediction of lung cancer.

Authors:  Margaret R Spitz; Waun Ki Hong; Christopher I Amos; Xifeng Wu; Matthew B Schabath; Qiong Dong; Sanjay Shete; Carol J Etzel
Journal:  J Natl Cancer Inst       Date:  2007-05-02       Impact factor: 13.506

4.  Cumulative association of five genetic variants with prostate cancer.

Authors:  S Lilly Zheng; Jielin Sun; Fredrik Wiklund; Shelly Smith; Pär Stattin; Ge Li; Hans-Olov Adami; Fang-Chi Hsu; Yi Zhu; Katarina Bälter; A Karim Kader; Aubrey R Turner; Wennuan Liu; Eugene R Bleecker; Deborah A Meyers; David Duggan; John D Carpten; Bao-Li Chang; William B Isaacs; Jianfeng Xu; Henrik Grönberg
Journal:  N Engl J Med       Date:  2008-01-16       Impact factor: 91.245

Review 5.  Molecular genetics of head and neck cancer.

Authors:  Lyon L Gleich; Frank N Salamone
Journal:  Cancer Control       Date:  2002 Sep-Oct       Impact factor: 3.302

6.  The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial.

Authors:  F R Khuri; E S Kim; J J Lee; R J Winn; S E Benner; S M Lippman; K K Fu; J S Cooper; E E Vokes; R M Chamberlain; B Williams; T F Pajak; H Goepfert; W K Hong
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-08       Impact factor: 4.254

7.  Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients.

Authors:  Fadlo R Khuri; J Jack Lee; Scott M Lippman; Edward S Kim; Jay S Cooper; Steven E Benner; Rodger Winn; Thomas F Pajak; Brendell Williams; George Shenouda; Ian Hodson; Karen Fu; Dong M Shin; Everett E Vokes; Lei Feng; Helmuth Goepfert; Waun Ki Hong
Journal:  J Natl Cancer Inst       Date:  2006-04-05       Impact factor: 13.506

Review 8.  Perspectives on the molecular epidemiology of aerodigestive tract cancers.

Authors:  Rayjean J Hung; Olga van der Hel; Sean V Tavtigian; Paul Brennan; Paolo Boffetta; Mia Hashibe
Journal:  Mutat Res       Date:  2005-07-14       Impact factor: 2.433

9.  EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups.

Authors:  N van Zandwijk; O Dalesio; U Pastorino; N de Vries; H van Tinteren
Journal:  J Natl Cancer Inst       Date:  2000-06-21       Impact factor: 13.506

10.  Prevention of second primary tumours with etretinate in squamous cell carcinoma of the oral cavity and oropharynx. Results of a multicentric double-blind randomised study.

Authors:  M Bolla; R Lefur; J Ton Van; C Domenge; J M Badet; Y Koskas; A Laplanche
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.